Mizuho (NYSE:MFG) analysts maintained a Neutral rating on Revance Therapeutics (NASDAQ:RVNC), a $382 million market cap company, with a steady price target of $3.65. The firm's stance came in the wake ...
In a report released today, Vijay Rakesh from Mizuho Securities maintained a Hold rating on Mobileye Global, Inc. Class A (MBLY – Research ...
Japan's Rakuten Group has decided not to seek a listing for Rakuten Securities on the Tokyo Stock Exchange, it said on ...
Mizuho Equity TCA is an application that allows clients to conduct pre-trade and post-trade analysis of their Japanese equities trades. The post-trade tool provides users with a post-trade execution ...
Yet "the bond market has not taken on board" the potential for 3% inflation in 2025, Steven Ricchiuto, chief economist at Mizuho Securities, wrote in a Monday client note. Even before December's ...
Geneos Wealth Management Inc. lessened its holdings in shares of The Clorox Company (NYSE:CLX – Free Report) by 8.3% during ...
For doing more than its peers to connect issuers and investors, Mizuho Securities is IFR’s Yen Bond House of the Year. Tightening currency basis swaps, easing geopolitical tensions between the US ...
MIDLAND, Texas, Jan. 30, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: VNOM) (“Viper”) announced today the launch of an underwritten ...
Qorvo (NASDAQ:QRVO) shares fell 0.5% in premarket trading on Friday, even as Mizuho Securities upped its earnings estimates on the involvement of activist investor Starboard Value. Mizuho analyst ...
Mizuho Financial Group, Inc. operates as a holding company which engages in the provision of financial services such as banking, trust banking, securities, and others. It operates through the ...
Securities adjusted its outlook on Sage Therapeutics (NASDAQ:SAGE) shares, with analyst Vamil Divan increasing the price target to $9.00 from the previous $6.00, while maintaining a Neutral rating on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback